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Research
The public health burden of psychiatric dis-
orders such as depression and anxiety is tre-
mendous—an estimated 450 million people 
worldwide suffer from psychiatric disorders 
[World Health Organization (WHO) 2001]. 
In the United States, the lifetime preva-
lence of major depressive disorder [using 
survey ascertainment of symptoms consis-
tent with Diagnostic and Statistical Manual 
of Mental Disorders (DSM) diagnostic crite-
ria (American Psychiatric Association 1987, 
1994)] is approximately 10% for men and 
20% for women (Kessler et al. 1994; Steffens 
et al. 2000). Furthermore, very high percent-
ages of older people suffer from depressive 
(10–30%) or anxiety (~ 20%) symptoms that 
do not meet full diagnostic criteria (Beekman 
et al. 1999; Himmelfarb and Murrell 1984) 
but are associated with excess morbidity 
and functional impairment (Beekman et al. 
1999; de Beurs et al. 1999; Himmelfarb and 
Murrell 1984; Lyness et al. 2007), greater risk 
of subsequent clinical diagnoses of depression 
and anxiety (Horwath et al. 1992; van’t Veer-
Tazelaar et al. 2009), and greater health care 
service use and costs (de Beurs et al. 1999; 
Simon et al. 1995). Improved understanding 
of risk factors for anxiety and depressive 
symptoms could help address the public 
health burden of these disorders.
Few studies have considered the possible 
link between environmental toxicant expo-
sures at low levels found in the community 
and mental health outcomes, despite the evi-
dence from occupational studies that aspects 
of mood may be particularly sensitive to such 
exposures (Johnson et al. 1987). Given that 
many toxicant exposures are potentially modi-
fiable, this group of potential risk factors for 
mental health outcomes should be of interest. 
Lead exposure is of particular interest because 
it is an established neurotoxicant (Bressler et al. 
1999) with known effects on several brain 
systems implicated in depression and anxi-
ety, including monoaminergic signaling (Kala 
and Jadhav 1995; Lasley et al. 1984; Virgolini 
et al. 2005) and the hypothalamic–pituitary–
adrenal (HPA) axis (Cory-Slechta et al. 2008; 
Virgolini et al. 2005). Lead exposure is also 
a known risk factor for many cardiovascular 
end points (Eum et al. 2011; Navas-Acien 
et al. 2007; Weisskopf et al. 2009), which 
have also been demonstrated to be associ-
ated with adverse psychological symptoms, 
particularly in older adults (Alexopoulos et al. 
1997; Vink et al. 2008). Furthermore, several 
studies among occupationally exposed adults 
have found lead exposure to be related to 
mood disorders and psychological symptoms 
(Balbus-Kornfeld et al. 1995; Schwartz et al. 
2005; Shih et al. 2007). However, large-scale 
epidemiological studies of low-level environ-
mental exposure to lead and psychological 
symptoms have been conducted in only two 
settings, the Normative Aging Study (NAS) 
and the National Health and Nutrition 
Examination Survey (NHANES), with some 
studies (Bouchard et al. 2009; Rajan et al. 
2007; Rhodes et al. 2003), but not all (Golub 
et al. 2010), suggesting associations.
Only one of the prior studies of low-level 
lead exposure and mental health included 
older women, and even in that study the 
average age was only 46.5 years (Golub 
et al. 2010). Focusing on women of all ages 
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Ba c k g r o u n d: Different lines of evidence suggest that low-level lead exposure could be a modifiable 
risk factor for adverse psychological symptoms, but little work has explored this relation. 
oB j e c t i v e: We assessed whether bone lead—a biomarker of cumulative lead exposure—is associated 
with depression and anxiety symptoms among middle-age and elderly women.
Me t h o d s : Participants were 617 Nurses’ Health Study participants with K-shell X-ray fluorescence 
bone lead measures and who had completed at last one Mental Health Index 5-item scale (MHI-5) 
and the phobic anxiety scale of the Crown-Crisp Index (CCI) assessment at mean ± SD age of 
59 ± 9 years (range, 41–83 years). With exposure expressed as tertiles of bone lead, we analyzed 
MHI-5 scores as a continuous variable using linear regression and estimated the odds ratio (OR) of 
a CCI score ≥ 4 using generalized estimating equations.
re s u l t s: There were no significant associations between lead and either outcome in the full sample, 
but associations were found among premenopausal women and women who consistently took 
hormone replacement therapy (HRT) between menopause and bone lead measurement (n = 142). 
Compared with women in the lowest tertile of tibia lead, those in the highest scored 7.78 points 
worse [95% confidence interval (CI): –11.73, –3.83] on the MHI-5 (p-trend = 0.0001). The corre-
sponding OR for CCI ≥ 4 was 2.79 (95% CI: 1.02, 7.59; p-trend = 0.05). No consistent associations 
were found with patella lead.
co n c l u s i o n s: These results provide support for an association of low-level cumulative lead expo-
sure with increased depressive and phobic anxiety symptoms among older women who are pre-
menopausal or who consistently take postmenopausal HRT.
key wo r d s: anxiety, depression, environmental exposure, epidemiology, lead, longitudinal study. 
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is critical because the prevalence of mood 
disorders and anxiety is twice as common 
in women as in men (Beekman et al. 1999; 
Kessler et al. 1994), and measures of cumu-
lative exposure to lead may be of particular 
importance. Therefore, we explored the asso-
ciation between cumulative lead exposure—as 
measured by lead in bone—and mental health 
among middle-age and elderly women partici-
pating in the Nurses’ Health Study (NHS). 
Because of the influence of menopause and 
subsequent hormone replacement therapy 
(HRT) on bone dynamics (Nelson et al. 
2002; Seeman 2003), including the accumu-
lation of lead in bone, we also examined the 
influence of these factors.
Materials and Methods
Study population. The NHS is a cohort of 
121,700 registered nurses recruited between 
the ages of 30 and 55 years in 1976 and fol-
lowed up via biennial mailed questionnaires 
(Colditz et al. 1997). Our study population 
was drawn from two subsamples of the NHS 
cohort that was evaluated for lead exposure. 
The first is a sample of women who partici-
pated in a case–control study of lead expo-
sure and hypertension (Korrick et al. 1999). 
Women were invited to participate if they 
lived in the Greater Boston metropolitan area, 
Massachusetts, were not obese (body mass 
index < 29 kg/m2), and did not have a history 
of major, chronic disease—mental health prob-
lems were not an exclusion criterion. Women 
who first reported a diagnosis of hypertension 
between 1990 and 1994 were invited to par-
ticipate as cases; women free of major chronic 
disease participted as controls and were fre-
quency matched to cases by 5-year age groups. 
In total, between 1993 and 1995, 302 NHS 
participants agreed to participate.
The women in the second sample were 
recruited for a study of lead exposure and 
osteoporosis. Similar eligibility criteria used 
for controls in the hypertension study were 
applied, with participants being free of 
chronic diseases (not including mental health 
problems) up to the time of recruitment 
(2001 through 2004), at which time they 
underwent their lead exposure measurements. 
This sample comprised 320 NHS partici-
pants. Altogether, lead content was measured 
in cortical (tibia) and trabecular (patella) bone 
in 621 and 620 women, respectively, from 
these two studies. After providing a complete 
description of the study to the participants, 
written informed consent was obtained before 
participation in each substudy. The present 
study was approved by the institutional review 
boards of the Brigham and Women’s Hospital 
and the Harvard School of Public Health.
Measures of psychological symptoms 
were obtained as part of several of the 
regular biennial NHS mailed questionnaires. 
Depressive symptoms were measured using 
the Mental Health Index 5-item (MHI-5) 
subscale, which was included on the 1992, 
1996, and 2000 questionnaires. Anxiety 
symptoms were measured using the phobic 
anxiety scale of the Crown-Crisp Index (CCI) 
which was included on the 1988 and 2004 
questionnaires. Of the 621 women who 
participated in the lead exposure studies, 617 
completed at least one psychological symptom 
assessment. Of these 617 women, 613 (99.4%) 
completed at least one MHI-5 questionnaire, 
and 609 (98.7%) completed at least one CCI 
questionnaire. Individual women completed 
the MHI-5 in up to three separate study cycles 
for a total of 1,696 MHI-5 assessments, and 
the CCI in up to two separate study cycles 
for a total of 1,117 CCI assessments. We 
excluded 26 MHI-5 assessments (1.5%) and 
17 CCI assessments (1.5%) for which data 
were missing on pack-years of smoking (n = 10 
women). Thus, the final analytic sample 
included 603 women with 1,670 MHI-5 
assessments (24 women with one, 91 with 
two, and 488 with three), and 599 women 
with 1,100 CCI assessments (98 women with 
one and 501 with two; Figure 1). All responses 
to the 2004 CCI (n = 554) occurred after bone 
lead measurement, whereas all responses to the 
1988 CCI (n = 546) occurred before the bone 
lead measurements (mean ± SD, 10.0 ± 4.2 
years; range, 4.4–15.9 years). Of the MHI-5 
assessments, 1,102 (66.0%) occurred before 
the bone lead measurements (5.1 ± 3.5 years 
earlier; range, 0.4–12 years). Because bone 
lead reflects many years of past exposure, we 
included all psychological assessments in our 
primary analyses regardless of their timing 
with respect to bone lead measurement. 
Nonetheless, we also did sensitivity analyses 
restricted to those psychological assessments 
that occurred after bone lead measurement.
Lead exposure assessment. Participants vis-
ited the outpatient General Clinical Research 
Center of the Brigham and Women’s Hospital 
for measurement of lead content in their 
bone by K-shell X-ray fluorescence (KXRF) 
(Aro et al. 1994), expressed as micrograms of 
lead per gram of bone mineral (micrograms 
per gram). Bone lead measurements were 
taken at each woman’s midtibial shaft and 
patella. These sites are targets for bone lead 
research, because the half-life of lead in tibia 
and patella differs. In a cohort of older men, 
the half-life of lead in patella has been esti-
mated to be on the order of years, whereas 
in tibia it is estimated to be on the order of 
decades (Wilker et al. 2011). Among women, 
however, faster bone turnover (Seeman 2003) 
likely makes these half-lives shorter.
When we began measuring the women’s 
bone lead, we used an instrument developed 
by ABIOMED Inc. (Danvers, MA) (Burger 
et al. 1990). In 1999, we replaced our pro-
totype ABIOMED instrument with an 
upgraded instrument designed to improve 
measurement precision (Aro et al. 1994). 
Intercalibration data from persons who were 
measured on both instruments demonstrated 
a linear relationship between the two mea-
surements with a slope of 0.87. Using this 
correction factor, we are able to combine data 
from our prototype and upgraded KXRF 
machines (Nie et al. 2008). To reduce the 
impact of any additional scaling differences in 
these readings on our epidemiologic analyses, 
we included in all of our bone lead regression 
models a term for lead substudy, which effec-
tively adjusts for instrument, because women 
from the hypertension substudy were assessed 
on the ABIOMED instrument, and women 
from the osteoporosis substudy were assessed 
on the upgraded instrument.
Psychological  symptom  assessment. 
Symptoms of depression and anxiety were 
assessed with the MHI-5 and the CCI, respec-
tively, each of which has been validated and 
has an extensive history in research and been 
used in populations of a similar age as ours 
(Albert et al. 2005; Beusterien et al. 1996; 
Burgess et al. 1987; Friedman et al. 2005). The 
MHI-5 is a five-item subscale derived from the 
Short Form-36 health status survey designed 
to capture, among other aspects of psychologi-
cal functioning, psychological distress versus 
well-being (Ware and Sherbourne 1992). The 
Figure 1. Timeline of MHI-5 and CCI assessments among women with bone lead measurements from study 
subsample 1 (A) and subsample 2 (B), as described in “Materials and Methods.”
Calendar year Calendar year
88 90 92
Bone lead (1993–1995; n = 302) Bone lead (2001–2004; n = 319)
94 96 98 00 02 04 88 90 92 94 96 98 00 02 04
(n = 269) (n = 253) (n = 287) (n = 287) (n = 293)
(n = 291) (n = 263) (n = 267) (n = 279)
(n = 281)
MHI-5 (total 307 women, 833 MHI-5)
CCI (total 305 women, 558 CCI)
MHI-5 (total 296 women, 837 MHI-5)
CCI (total 294 women, 542 CCI)Cumulative lead exposure and depression and anxiety
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MHI-5 asks respondents how much of the time 
over the past month (all, most, good bit, some, 
little, or none; ranked 1–6) they felt nervous, 
felt so down that nothing could cheer them up, 
felt calm and peaceful, felt down and blue, or 
felt happy. The two positively worded questions 
are reverse coded so that lower scores indicate 
more depressive symptoms; all item scores are 
summed, and then the sum is rescaled to obtain 
a total score ranging from 0 to 100 (Ware et al. 
2000). An MHI-5 score < 60 denotes the pres-
ence of severe depressive symptoms and predicts 
major depression as identified using the Mini-
International Neuropsychiatric Interview Major 
Depressive Episode module with high sensi-
tivity and specificity among adults ≥ 65 years 
of age (Friedman et al. 2005). We also used 
an alternative cutoff score of < 53, which has 
been validated for identifying major depression 
in younger populations (Berwick et al. 1991; 
Holmes 1998).
The phobic anxiety scale of the CCI mea-
sures personality symptoms of phobic anxiety 
(Crown and Crisp 1966). It is a brief self-
rating inventory of eight questions on com-
mon phobias—such as fear of enclosed spaces, 
illness, going out alone, heights, and crowds—
with two yes or no questions (scored 2 or 0) 
and six three-level response questions (e.g., 
never/sometimes/often or not at all/moder-
ately/very; scored 0/1/2). Scores range from 
0 to 16, with higher scores corresponding with 
higher levels of phobic anxiety. The CCI has 
been validated in psychiatric outpatient clinic 
settings and found to discriminate patients 
with anxiety disorders and agoraphobia from 
those with other mental health disorders 
(Mavissakalian and Michelson 1981). The 
validity of the phobic anxiety subscale of the 
CCI in the NHS population has been tested 
previously, where scores were shown to be 
associated with use of tranquilizer medications 
(Albert et al. 2005). A CCI score of ≥ 4 has 
been related to several adverse outcomes in 
the NHS population, for example, Parkinson’s 
disease (Weisskopf et al. 2003), coronary heart 
disease, and sudden coronary death (Kawachi 
et al. 1994; Whang et al. 2009).
Statistical analysis. We used the generalized 
linear model framework to analyze repeated 
outcome measurements and used an unstruc-
tured covariance matrix to account for corre-
lations in scores within individuals. Primary 
analyses treated MHI-5 scores as a continuous 
variable. Because the distribution of scores on 
the CCI was skewed, we used generalized esti-
mating equations to estimate odds ratios (ORs) 
and 95% confidence intervals (CIs) for scoring 
≥ 4 on any CCI measurement (i.e., high phobic 
anxiety; n = 188 women, 244 assessments). We 
conducted additional analyses using this same 
approach to estimate ORs for scoring < 60 
on the MHI-5 (i.e., severe depressive symp-
toms; n = 96 women, 121 assessments) or the 
alternative cutoff of < 53. When using dichoto-
mous outcomes, additional sensitivity analyses 
were performed that included as “cases” women 
taking antidepressant or antianxiety medication 
who did not meet criteria for major depression 
by MHI-5 scores (n = 63 women; 84 observa-
tions) or high phobic anxiety by CCI scores 
(n = 56 women; 56 observations)—along with 
women who were cases based on their symptom 
scores. For women missing one or two CCI 
responses (n = 55 women, 57 observations) 
or one MHI-5 response (n = 44 women, 46 
observations), we used the standard approach 
of imputing the total score for the scale by 
dividing their score by the fraction of questions 
answered and rounding to the nearest integer 
(DeVellis 1991; Ware et al. 2000).
We specifically addressed the potential 
impact of menopause status in separate 
analyses. Menopause is associated with 
increased bone turnover that mobilizes 
stored lead from bone into circulating blood, 
increasing blood lead levels (Korrick et al. 
2002). An increased rate of bone remodeling 
means that the lead concentration in bone is 
increasingly in flux during this period, which 
may compromise the utility of the bone lead 
concentration as a measure of cumulative lead 
exposure. Bone turnover with menopause 
is reduced in women who have taken HRT 
(Nelson et al. 2002). Therefore, we conducted 
additional analyses restricted to women 
either who were premenopausal at bone lead 
measurement (n = 45) or who had consistently 
taken HRT between menopause and bone 
lead measurement (n = 97). Menopausal 
status was based on each woman’s self report 
on the regular NHS biennial questionnaires 
of permanent cessation of natural menses, as 
well as the age at which this occurred. For 
women who underwent hysterectomy without 
bilateral oophorectomy, a life table was used to 
assign an age at menopause based on the date 
of surgery, smoking, and hormonal status.
We performed separate analyses for patella 
and tibia bone lead biomarkers. Bone lead ter-
tiles were calculated based on the distributions 
among women who were premenopausal or 
consistently on HRT between menopause and 
bone lead measurements. Covariates in our 
models were obtained from biennial question-
naires and included age (years) at psychological 
symptom measurement, education (registered 
nurse, bachelor’s degree, master’s or doctor-
ate degree), alcohol consumption (tertiles of 
grams per day: < 1.8, 1.8–8.69, ≥ 8.7), and 
pack-years of smoking (0 and tertiles among 
smokers: 1–8.9, 9–21.9, ≥ 22), because these 
variables have been associated with lead expo-
sure and psychological symptoms (Bjelland 
et al. 2008; Boden and Fergusson 2011; Hu 
et al. 1996; Kessler et al. 1994; Korrick et al. 
2002; Theppeang et al. 2008; Wiesbeck et al. 
2008). We also included husband’s education 
(high school or less, college education, gradu-
ate school, or not married) and employment 
status at psychological symptom measure-
ment (retired/homemaker, part-time worker, 
full-time worker) as indicators of socioeco-
nomic status, which may be related to both 
lead exposure and psychological symptoms 
(Kessler et al. 1994; Theppeang et al. 2008). 
We adjusted for substudy to account for both 
the different KXRF machines used in the two 
substudies, as well as secular trends in lead 
exposure and possibly psychological symp-
tom reporting, and age (years) at bone lead 
measurement, which is related to measured 
bone lead concentrations (Wilker et al. 2011). 
About half of the participants were women 
from a case–control study of hypertension. 
Because the selection of hypertension cases 
and controls could have introduced selec-
tion bias, we conducted additional sensitivity 
analyses adjusting for hypertensive status in 
this substudy. Hypertension cases were iden-
tified based on self-reported physician diag-
nosis on the NHS biennial questionnaires. 
We also conducted sensitivity analyses adding 
adjustment for whether the nurse’s parents 
owned their own home when she was born, 
an additional socioeconomic status indicator 
that reflects status in childhood. The women 
responded to items on some covariate data in 
more than one questionnaire cycle, and for 
our analyses, we used responses from the NHS 
questionnaire closest to the psychological 
symptom assessment. We used missing indi-
cator variables for the small amount of miss-
ing data. Tests for trend with increasing lead 
concentration were computed by including 
a continuous term for lead that was formed 
by assigning to each woman the median lead 
concentration of the tertile in which she was 
classified. This approach minimizes the influ-
ence of extreme exposure values. A two-sided 
p-value ≤ 0.05 was considered statistically sig-
nificant. We conducted all analyses in SAS 
(version 9; SAS Institute Inc., Cary, NC).
Results
The mean ± SD (range) age of women in our 
study was 60.9 ± 6.0 (46–74) years at the 
time of lead measurement. Age at the time of 
MHI-5 assessment was 59.4 ± 7.3 (45–79) 
years, and at CCI assessment was 59.2 ± 10.2 
(41–83) years. The mean ± SD levels of tibia 
lead and patella lead were 10.3 ± 9.5 μg/g and 
12.5 ± 11.2 μg/g, respectively. As has been 
previously reported (Korrick et al. 2002), 
both patella and tibia bone lead levels were 
higher with older age, more pack-years of 
smoking, and alcohol consumption (Table 1). 
There were less consistent associations 
between other covariates and bone lead levels. 
Although MHI-5 and CCI were designed to 
target different types of psychological distress, 
they are often correlated because depression Eum et al.
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and anxiety are highly comorbid (Byers et al. 
2010; Kessler et al. 1994). In our population, 
MHI-5 and CCI assessments were done in 
different years of the NHS, and Spearman 
correlations for these two exams, which 
ranged from –0.22 to –0.34, were modest.
In analyses of all women, depressive 
symptoms were inconsistently worse with 
higher tibia lead levels (Table 2). Compared 
with the lowest tertile of tibia lead concen-
tration, women in the middle tertile scored 
1.70 MHI-5 points worse (95% CI: –3.75, 
0.34), and those in the highest tertile scored 
1.1 points worse (95% CI: –3.1, 0.94). At the 
time of bone lead measurement, most of the 
women (n = 572) were postmenopausal, with 
a mean ± SD of 12.2 ± 6.5 years since meno-
pause. In analyses restricted to premenopausal 
women and postmenopausal women who 
were consistently on HRT, MHI-5 scores 
decreased monotonically with increasing tibia 
lead. Compared with women in the lowest 
tertile of tibia lead concentration, women in 
the middle and highest tertiles scored 4.31 
(95% CI: –7.88, –0.74) and 7.78 (95% CI: 
–11.73, –3.83) points lower, respectively, on 
the MHI-5 (Table 2). In sensitivity analyses 
either restricting the analyses to MHI-5 assess-
ments that occurred after bone lead measure-
ment or restricting to women who scored < 4 
on both CCI assessments, results were similar 
[see Supplemental Material, Table 1 (http://
dx.doi.org/10.1289/ehp.1104395)].
When lead was modeled as a continu-
ous variable, there was a 5.63-point reduc-
tion (95% CI: –8.49, –2.78) in MHI-5 
score per 1 SD higher tibia lead (9.5 μg/g) 
among premenopausal women and post-
menopausal women consistently on HRT 
[see Supplemental Material, Table 1 (http://
dx.doi.org/10.1289/ehp.1104395)]. When we 
dichotomized MHI-5 scores as < 60 (severe 
depression symptoms) or at least 60, among 
premenopausal women and postmenopausal 
women consistently on HRT (n = 37 MHI-5 
assessments < 60), the OR for severe depres-
sion symptoms for women in the highest 
tertile of tibia lead was 3.71 (95% CI: 1.18, 
11.64; p-trend = 0.02) compared with women 
in the lowest tertile. In analyses of all women, 
the OR for depression for women in the high-
est, compared with lowest, tibia tertile was 
1.42 (95% CI: 0.81, 2.46). These results were 
similar using the alternative MHI-5 cutoff of 
< 53 (Berwick et al. 1991; Holmes 1998), but 
fewer women met this threshold, so confidence 
limits were much larger (data not shown).
A similar pattern was apparent for anxi-
ety symptoms. Tibia bone lead concentra-
tion was not associated with CCI scores in 
the overall population (Table 3). The stron-
gest association appeared in analyses among 
premenopausal and postmenopausal women 
consistently on HRT. In this subset, the 
ORs for severe phobic anxiety (CCI ≥ 4) for 
women in the middle and highest tertiles 
of tibia lead concentration, compared with 
those in the lowest tertile, were 1.52 (95% 
CI: 0.60, 3.82) and 2.79 (95% CI: 1.02, 
7.59; p-trend = 0.05), respectively (Table 3). 
All of these results were similar in sensitiv-
ity analyses restricted to the CCI assessments 
that occurred after bone lead measurement 
[see Supplemental Material, Table 2 (http://
dx.doi.org/10.1289/ehp.1104395)]. When 
lead was modeled as a continuous variable, 
the OR for high phobic anxiety was 2.06 
(95% CI: 1.01, 4.22) per 1 SD higher tibia 
lead (9.5 μg/g) among premenopausal women 
and postmenopausal women consistently on 
HRT (see Supplemental Material, Table 2).
In general, we found much weaker, incon-
sistent, or null associations between patella 
lead concentration and either outcome. 
However, among premenopausal women 
and postmenopausal women consistently 
on HRT, in MHI-5 analyses restricted to 
those assessments that occurred after bone 
lead measurement, there was some sugges-
tion of higher MHI-5 score (less depression) 
with higher patella lead [see Supplemental 
Material, Table 1 (http://dx.doi.org/10.1289/
ehp.1104395)]. There was also a significant 
decrease in anxiety symptoms in the highest 
tertile of patella bone lead among premeno-
pausal women and postmenopausal women 
consistently on HRT (Table 3). However, 
this association was seen only in the high-
est tertile, and precision was poor because of 
small numbers (n = 10 “cases”); the results 
in this tertile likely also drove the significant 
association with the continuous patella lead 
term (see Supplemental Material, Table 2).
All results were essentially unchanged upon 
additional adjustment for hypertension at bone 
lead measurement or for whether the nurse’s 
Table 1. Levels of lead exposure biomarkers (μg/g) by characteristic among women with measures of 
psychological symptoms (n = 617).
Tibia lead Patella lead
Characteristica n Mean ± SD Median nb Mean ± SD Median
Age at lead exposure assessment (years)
< 55 95 9.2 ± 7.4 8.7 95 12.8 ± 9.6 11.3
55–59 143 9.2 ± 8.6 9.0 143 10.8 ± 10.0 10.4
60–64 194 9.3 ± 9.7 9.0 194 12.1 ± 11.1 13.0
65–69 142 12.9 ± 10.3 13.0 142 13.1 ± 12.4 12.1
≥ 70 43 12.9 ± 11.4 12.2 42 17.3 ± 13.6 16.1
Education in 1992
Registered nurse diploma 351 10.4 ± 9.6 10.0 350 13.3 ± 10.7 12.2
Bachelor’s degree 161 10.6 ± 8.8 9.6 161 10.6 ± 12.1 11.3
Master’s or doctorate degree 72 8.6 ± 10.9 8.0 72 12.6 ± 12.1 11.7
Missing 33 12.2 ± 9.6 11.0 33 12.2 ± 10.0 14.0
Husband education in 1992
High school or less 144 11.6 ± 10.1 10.7 143 14.2 ± 12.6 13.0
College education 157 10.0 ± 9.3 9.6 157 12.1 ± 11.7 11.3
Graduate school 168 9.5 ± 10.0 9.0 168 11.8 ± 10.4 11.7
No husband (not married) 70 10.6 ± 8.8 10.0 70 12.2 ± 11.0 12.2
Missing 78 10.4 ± 8.4 9.3 78 11.7 ± 9.3 12.2
Employment status in 2004
Retired/homemaker 305 11.5 ± 10.3 10.4 304 14.0 ± 11.1 13.0
Part-time worker 90 9.5 ± 9.1 10.0 90 9.0 ± 11.9 9.8
Full-time worker 170 8.9 ± 8.4 8.0 170 11.7 ± 11.1 12.2
Missing 52 9.6 ± 8.2 9.3 52 12.1 ± 9.8 12.2
Pack-years of cigarette smoking as of 2004
0 239 9.6 ± 8.8 9.0 238 11.0 ± 10.4 11.7
1–8.9 110 9.2 ± 8.8 9.0 110 11.8 ± 8.8 11.3
9–21.9 122 10.8 ± 10.6 10.7 122 13.0 ± 13.0 10.7
22–80 136 12.1 ± 10.0 10.9 136 15.1 ± 12.2 14.0
Missing 10 11.8 ± 11.1 11.7 10 12.8 ± 13.0 11.3
Alcohol consumption in 2002 (g/day)
< 1.8 218 9.3 ± 8.5 9.6 217 11.5 ± 10.5 12.0
1.8–8.69 189 10.4 ± 9.3 9.0 189 12.6 ± 11.7 12.2
≥ 8.7 210 11.3 ± 10.6 10.4 210 13.3 ± 11.5 12.2
Study subsample
Lead and hypertension sample 302 11.7 ± 7.8 10.4 302 15.1 ± 9.5 13.5
Lead and osteoporosis sample 315 9.1 ± 10.8 8.0 314 9.9 ± 12.2 10.0
Postmenopausal hormone use at lead exposure assessment
Premenopausal (never user) 45 9.1 ± 7.6 8.7 45 11.9 ± 10.4 12.2
Continuous user after menopause 97 9.6 ± 7.8 9.0 97 12.5 ± 9.1 11.3
Never user or inconsistent user 475 10.6 ± 10.0 10.0 474 12.5 ± 11.7 12.2
aVariables were determined in different years based on date of questionnaire or measure as part of the parent NHS. 
Bone lead levels were standardized to account for differences between measures done before versus after 1999. 
bn = 616 for patella lead analyses because of missing patella lead data.Cumulative lead exposure and depression and anxiety
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parents owned their own home when she was 
born, an indicator of childhood socioeconomic 
status (data not shown). Analyses restricted 
to women with no missing MHI-5 or CCI 
responses showed similar results. Although 
there were too few premenopausal women to 
analyze this group separately, analyses restricted 
to postmenopausal women consistently on 
HRT between menopause and bone lead mea-
surement (n = 97) were similar to analyses that 
also included women who were premenopausal 
(data not shown). Among women who were 
premenopausal and postmenopausal women 
who were consistently on HRT, analyses of 
dichotomized outcomes also yielded similar 
results when we included as “cases” women tak-
ing antidepressant or antianxiety medication—
regardless of their MHI-5 or CCI score—along 
with women who were cases based on their 
symptom scores (data not shown).
Discussion
We found increased depressive symptom 
scores and high phobic anxiety scores in asso-
ciation with increasing tibia, but not patella, 
bone lead concentration among women who 
were either premenopausal or postmenopausal 
and consistently on HRT between meno-
pause and bone lead measurement. These 
associations were independent of age, educa-
tion, husband’s education, cigarette smok-
ing, alcohol intake, and employment status. 
These results were observed among women 
with low blood lead concentrations consistent 
with nonoccupational background popula-
tion exposures and presumed relatively low 
cumulative exposures (Table 1). The geomet-
ric mean blood lead concentration among our 
women was 2.37 μg/dL, which is similar to 
levels seen among women of comparable age 
in NHANES data from the same time periods 
(Jackson et al. 2010; Pirkle et al. 1998).
That the association was seen among pre-
menopausal and postmenopausal women on 
HRT, rather than among the full sample, 
could be the result of less bone loss in these 
women compared with postmenopausal 
women who did not consistently take HRT 
(Nelson et al. 2002). Specifically, associa-
tions may have been attenuated for all women 
combined if tibia bone lead levels were a less 
accurate marker of cumulative lead exposure 
in postmenopausal women that were not tak-
ing HRT, a possible result of measurement 
error resulting from variation in the degree of 
bone turnover among these women. A bio-
logical interaction between HRT and lead that 
results in greater effects among HRT users 
is an alternative possibility. That the results 
are due to chance in this subgroup also can-
not be ruled out. We observed an unexpected 
inverse association between patella lead and 
anxiety symptoms among women who were 
premenopausal or postmenopausal on HRT, 
although this was likely driven by a small 
number of women with high patella lead con-
centrations [see Table 3; see also Supplemental 
Material, Table 2 (http://dx.doi.org/10.1289/
ehp.1104395)]. There was also some sug-
gestion of less MHI-5 depressive symptoms 
with higher patella lead in one of the suba-
nalyses (see Supplemental Material, Table 1), 
although this did not reach statistical signifi-
cance. Although we cannot dismiss the pos-
sibility that these associations are causal, they 
may also have arisen by chance. Otherwise, 
patella lead measures were generally not asso-
ciated with MHI-5 or CCI reported symp-
toms (Tables 2 and 3). The lack of consistent 
findings with patella lead suggests that the rel-
evant lead exposure window for depression or 
anxiety symptoms may be more long term and 
therefore better reflected by tibia lead, which 
has a longer half-life than patella lead. On the 
other hand, greater variability of patella lead 
measurements could also contribute to the 
predominantly null patella findings.
Limitations of this study include the 
possibility that our findings are driven by 
reverse causality. For example, given that 
phobic anxiety generally has onset at young 
ages (Kessler et al. 2005), early-life anxiety 
could affect socioeconomic position, smoking 
habits, or other risk factors for lead exposure 
and thereby increase later bone lead levels. 
Furthermore, it is possible that lower socio-
economic status earlier in life could indepen-
dently predict both later lead exposure and 
later phobic anxiety (or possibly depression), 
Table 2. Adjusteda differences in MHI-5 score by bone lead tertile.
All women Premenopausal or postmenopausal on HRTb
n (participants/MHI-5 
assessments)
MHI-5 n (participants/MHI-5 
assessments)
MHI-5
Lead biomarker Score (mean ± SD) Point difference (95% CI) Score (mean ± SD) Point difference (95% CI)
Tibia lead tertile (μg/g)
< 7.0 202/558 81 ± 12 Reference 46/129 83 ± 10 Reference
7.0–11.5 159/440 79 ± 13 –1.70 (–3.75, 0.34) 48/134 78 ± 15 –4.31 (–7.88, –0.74)
> 11.5 242/672 80 ± 13 –1.06 (–3.05, 0.94) 47/126 76 ± 13 –7.78 (–11.73, –3.83)
p-Trend 0.33 0.0001
Total 603/1,670 80 ± 13 141/389 79 ± 13
Patella lead tertile (μg/g)
< 8.5 193/532 79 ± 12 Reference 47/128 80 ± 13 Reference
8.5–14.5 179/501 80 ± 13 1.02 (–1.06, 3.11) 49/135 78 ± 14 –0.66 (–5.00, 3.67)
> 14.5 230/634 80 ± 13 0.61 (–1.55, 2.78) 45/126 79 ± 12 0.51 (–3.91, 4.94)
p-Trend 0.64 0.77
Total 602/1,667 80 ± 13 141/389 79 ± 13
aAdjusted for substudy group, age at bone lead and at MHI-5 measurement, education, husband’s education, alcohol consumption, pack-years of smoking, and employment status at 
MHI-5 measurement; lower scores indicate more depressive symptoms (lower MHI-5 scores indicate worse symptoms). bWomen who were either premenopausal at the time of bone 
lead measurement (n = 45) or consistently on HRT between menopause and bone lead measurement (n = 97). 
Table 3. Adjusteda ORs and 95% CI of high phobic anxiety (CCI ≥ 4) by bone lead tertile.
All women  
(n = 599; 1,100 assessmentsb)
Premenopausal or postmenopausal 
on HRTc (n = 140; 261 assessments)
Lead biomarkers CCI ≥ 4 (yes/no) OR (95% CI) CCI ≥ 4 (yes/no) OR (95% CI)
Tibia lead tertile (μg/g)
< 7.0 78/288 Reference 11/73 Reference
7.0–11.5 66/265 0.84 (0.54, 1.32) 21/83 1.52 (0.60, 3.82)
> 11.5 100/303 1.10 (0.73, 1.64) 20/53 2.79 (1.02, 7.59)
p-Trend 0.62 0.05
Patella lead tertile (μg/g)
< 8.5 80/270 Reference 16/71 Reference
8.5–14.5 78/254 0.96 (0.63, 1.47) 26/64 1.16 (0.41, 3.28)
> 14.5 86/330 0.75 (0.49, 1.16) 10/74 0.23 (0.07, 0.69)
p-Trend 0.17 0.003
aAdjusted for substudy group, age at bone lead and at CCI measurement, education, husband’s education, alcohol 
consumption, pack-years of smoking, and employment status at CCI measurement. bOnly 1,098 for patella lead analyses 
because of missing patella lead data. cWomen who were either premenopausal at the time of bone lead measurement 
(n = 45) or consistently on HRT between menopause and bone lead measurement (n = 97).Eum et al.
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thereby leading to a spurious association. 
However, both of these possibilities are argued 
against by the fact that our results were essen-
tially unchanged when adjusted for a marker 
of childhood socioeconomic status and pack-
years of smoking. All of this suggests that 
some phobic anxiety may be sensitive to later-
life risk factors. Also, the association between 
lead and CCI phobic anxiety score may not be 
restricted to phobic anxiety because the symp-
toms captured by the CCI scale have some 
overlap with other types of anxiety (Burgess 
et al. 1987; Crown and Crisp 1966).
Our data are limited to the available 
MHI-5 and CCI assessments for our study 
population; thus, we cannot determine whether 
the observed phobic anxiety symptoms are an 
exacerbation of previous symptoms from a 
younger age. Furthermore, neither the MHI-5 
nor the CCI are diagnostic tools. Despite these 
limitations, both assessments have demon-
strated strong relations with clinical disorders. 
In comparing scores on the MHI-5 with DSM-
based diagnoses, the area under the receiver 
operating characteristic curve was found to be 
quite high for depression (0.892) and anxi-
ety disorders (0.739) (Berwick et al. 1991). 
The latter likely reflects both the fact that the 
MHI-5 is not completely specific to depres-
sion symptoms and that there is frequently 
comorbidity between depression and anxiety. 
The CCI has been found to discriminate well 
between patients with anxiety disorders and 
agoraphobia and patients with other mental 
health disorders (Mavissakalian and Michelson 
1981). Furthermore, symptoms ascertained 
by these measures have been associated with 
a number of clinical outcomes known to cor-
relate with clinical depression and/or anxiety 
such as Parkinson’s disease (Weisskopf et al. 
2003), coronary heart disease, and sudden cor-
onary death (Kawachi et al. 1994; Whang et al. 
2009). Thus, despite limitations, there is strong 
evidence that the study measures capture clini-
cally relevant symptoms.
Low-level environmental exposure to lead 
and psychological distress has been explored 
only in two other settings, older men in the 
NAS and adult men and women in NHANES. 
Among 526 NAS men (67 ± 7 years, mean 
± SD), higher patella bone lead concentra-
tion was significantly associated with scoring 
worse on the phobic anxiety scale of the Brief 
Symptom Inventory (BSI), and higher blood, 
patella, and tibia lead were all associated with 
scoring worse on an index that combined the 
BSI anxiety, depression, and phobic anxiety 
scales (Rhodes et al. 2003). Slightly weaker 
associations were seen in a follow-up study of 
this cohort (Rajan et al. 2007). In data from 
1,987 men and women 20–39 years of age 
in the 1999–2004 NHANES cycles, higher 
blood lead level was significantly associated 
with prevalent diagnoses of major depressive 
disorder and panic disorder based on the 
fourth edition of the DSM, but not generalized 
anxiety disorder as assessed with the World 
Health Organization Composite International 
Diagnostic Interview (Bouchard et al. 2009). 
Bone lead concentration was not available 
in these data. A later study of 4,159 adults 
≥ 20 years of age in the 2005–2006 NHANES 
cycle did not find a significant association 
between blood lead and depression symptom 
scores on the Patient Health Questionnaire-9 
(PHQ-9), although PHQ-9 scores increased 
with increasing quintiles of blood lead concen-
tration (Golub et al. 2010).
Lead is a neurotoxicant (Bressler et al. 
1999) with known effects on neural systems 
that underlie mood and anxiety symptoms. 
For example, lead exposure has been found to 
specifically disrupt signaling in monoaminergic 
signaling systems that are frequent targets for 
medications to treat these symptoms (Haider 
et al. 2005; Kala and Jadhav 1995; Lasley 
et al. 1984; Virgolini et al. 2005). Lead can 
alter synaptic signaling and second-messenger 
systems much more generally, to a large 
extent as a result of its ability to substitute for 
calcium (Garza et al. 2006), and thus disrupt 
multiple neurotransmitter systems that 
are implicated in mood disorders (Werner 
and Covenas 2010; Wu et al. 2008). Lead 
exposure also disrupts the HPA axis leading to 
altered glucocorticoid and catecholaminergic 
signaling (Cory-Slechta et al. 2008; Virgolini 
et al. 2005), with mood disorder as a proposed 
consequence (Cory-Slechta et al. 2008). 
HPA axis function, corticotrophin-releasing 
hormone, and cortisol levels are found to 
be altered among people with depression 
compared with population norms or controls 
without psychiatric disease (Holsboer 2000; 
Vreeburg et al. 2009). Lead also has well-
known adverse effects on the cardiovascular 
system (Eum et al. 2011; Navas-Acien et al. 
2007; Weisskopf et al. 2009), and many 
cardiovascular risk factors have been found 
to predict depression. There is a high rate of 
depression among people with hypertension, 
diabetes, coronary artery disease, and stroke, 
as well as frequent occurrence of white matter 
hyperintensities and silent stroke (on brain 
magnetic resonance imaging) in geriatric 
depression. This has led to a vascular theory 
of depression that posits these factors disrupt 
neural systems in the prefrontal region of the 
brain (Alexopoulos et al. 1997; Vink et al. 
2008). Thus, lead exposure could be related 
to psychological distress in older women via 
cardiovascular effects.
Strengths of our study include having 
a large group of women with bone lead 
measurements—a marker of cumulative lead 
exposure—and extensive covariate data. One 
limitation is that the women who were recruited 
for the original lead exposure studies were, 
excepting the subset with hypertension, selected 
to be particularly healthy, which may have made 
it more difficult to identify associations between 
lead and psychological symptoms. Given 
lead’s association with a number of chronic 
diseases, including cardiovascular, renal, and 
neurocognitive disorders (Ekong et al. 2006; 
Navas-Acien et al. 2007; Shih et al. 2007), 
women excluded because of chronic disease may 
have been more likely to both have higher lead 
exposure and lead-related disorders, including 
psychiatric symptoms. We did not have data 
on family history of psychiatric disorders and so 
could not adjust analyses for this. An additional 
limitation is that we did not have standardized 
clinical assessments for psychiatric disorders. 
Although such assessments would have been 
useful for purposes of establishing DSM-
criteria disorders, our questionnaires include 
reliable and valid measures that have been 
used extensively for research purposes (Albert 
et al. 2005; Berwick et al. 1991; Burgess et al. 
1987; Kawachi et al. 1994; Mavissakalian and 
Michelson 1981; Weisskopf et al. 2003; Whang 
et al. 2009). Furthermore, there is growing 
consideration of the value of dimensional 
measurement of psychological symptoms, for 
example, characterizing symptoms continuously 
across a spectrum of severity as we have done 
(National Institute of Mental Health 2010). 
Nevertheless, we also found similar results using 
the cutoffs of < 60 or < 53 for the MHI-5, both 
of which have been validated against clinical 
measures (Berwick et al. 1991; Friedman et al. 
2005; Holmes 1998).
Conclusion
Our results provide support for associations 
between lead exposure and both depression 
and anxiety among older women with commu-
nity-level exposures. Specifically, these findings 
were present among premenopausal women 
and postmenopausal women consistently on 
HRT. This may relate to the reduced effec-
tiveness of bone lead as a cumulative marker 
of lead exposure in postmenopausal women 
not taking HRT, but this warrants further 
confirmation. These results were found among 
women with low lead exposure levels that were 
similar to their same-age peers in NHANES 
data. Thus, these findings underscore the need 
to consider environmental contaminants as 
risk factors for psychological distress.
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